Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Current Assets (2016 - 2026)

Pharma-Bio Serv filings provide 16 years of Current Assets readings, the most recent being $13.3 million for Q1 2026.

  • On a quarterly basis, Current Assets fell 14.23% to $13.3 million in Q1 2026 year-over-year; TTM through Jan 2026 was $13.3 million, a 14.23% decrease, with the full-year FY2025 number at $13.4 million, down 14.73% from a year prior.
  • Current Assets hit $13.3 million in Q1 2026 for Pharma-Bio Serv, roughly flat from $13.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $21.0 million in Q1 2022 to a low of $13.2 million in Q3 2025.
  • Median Current Assets over the past 5 years was $18.8 million (2024), compared with a mean of $17.3 million.
  • Biggest five-year swings in Current Assets: decreased 28.52% in 2022 and later rose 0.75% in 2023.
  • Pharma-Bio Serv's Current Assets stood at $19.9 million in 2022, then decreased by 2.72% to $19.4 million in 2023, then decreased by 19.08% to $15.7 million in 2024, then dropped by 14.73% to $13.4 million in 2025, then decreased by 0.47% to $13.3 million in 2026.
  • The last three reported values for Current Assets were $13.3 million (Q1 2026), $13.4 million (Q4 2025), and $13.2 million (Q3 2025) per Business Quant data.